Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005989 · ClinicalTrials.gov registry record · Phase 2
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Study locations
NCT00005989: Completed Phase 2 study of Lung Cancer, sponsored by Mayo Clinic.
NCT00005989 is a Phase 2 study of Lung Cancer that has completed, run by Mayo Clinic. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005989, a Phase 2 study of Lung Cancer, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or metastatic non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG tipifarnib
Study Locations (3)
Florida
- Mayo Clinic in Florida - Jacksonville
Illinois
- University of Chicago Cancer Research Center - Chicago
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-11 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
What the finished NCT00005989 record still lists
NCT00005989 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which tipifarnib is the first listed.
NCT00005989 reports a single indexed study location in Florida, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00005989 about?
NCT00005989 is a clinical study titled "R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or metastatic non-small cell lung cancer.
What is the current status of trial NCT00005989?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-11. Estimated completion is 2007-07.
What conditions does trial NCT00005989 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00005989?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00005989?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005989 being conducted?
This trial has 3 study locations across Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia